MetaVia Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 12, 2022 and accepted by EDGAR at Aug 12, 2022, 16:16 ET.
Management's discussion and analysis
As filed, 22,072 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes included elsewhere in this report and the audited financial statements and related notes for the fiscal year ended December 31, 2021 included in our Annual Report on Form 10-K (“2021 Form 10-K”) filed by the Company with the SEC on March 31, 2022.
Forward-Looking Statements
Certain statements in this Quarterly Report on Form 10-Q are forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are based on management’s beliefs, assumptions and expectations and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, cash flow, business development, and employees, our ability to execute on our strategic realignments, our clinical activities, benefits of our proposed products to patients, our expectations with respect to product development and commercialization efforts, potentially competitive product offerings, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses and other risks and uncertainties described in our filings with the SEC.
In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.
Forward-looking statements are subject to a number of risks and uncertainties that could cause actual events to adversely differ from the expectations indicated in these forward-looking statements, including without limitation, the risks and uncertainties described in our 2021 Form 10-K, and in this Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. We operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility that regulatory authorities do not accept our application or approve the marketing of our products, the possibility we may be unable to raise the funds necessary for the development and commercialization of our products, and those described in our filings with the SEC.
Overview
NeuroBo Pharmaceuticals, Inc. (the “Company,” “we,” “us” or “our”) is a clinical-stage biotechnology company focused on developing and commercializing novel pharmaceuticals to treat viral neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. For more information on our business and our four product candidates, ANA001, NB-01, NB-02 and Gemcabene, see “Business-Overview” in Part I, Item 1 of our Annual Report on From 10-K filed on March 31, 2022.
Recent Developments
COVID-19
The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to our operations and business plan. We have closely monitored recent COVID-19 developments, including the lifting of COVID-19 safety measures, the drop in vaccination rates, the implementation of, and reaction to, vaccine mandates, the spread of new strains or variants of coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. We are subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on our business is highly uncertain and difficult to predict, as the responses that we, other businesses and governments are taking continue to evolve. We continue to actively monitor the evolving effects of COVID-19 and the effects on our business and operations.
To date, except for the adjustments to scientific activity described under “Current Scientific Activity” below, we have not experienced any external changes in our business that would have a significant negative impact on our condensed consolidated statements of operations and comprehensive loss or cash flows.
Exclusive of the development of certain of our proposed therapies, the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our service providers, suppliers, contract research organizations and our clinical trials, all of which are uncertain and cannot be predicted. The economic effect of the COVID-19 pandemic combined with increased geopolitical uncertainty and rising inflation could result in a negative impact on us. As of the date of issuance of our financial statements, the extent to which the COVID-19 pandemic may in the future materially impact our financial condition, liquidity or results of operations is uncertain.
Current Scientific Activity
In light of the present business environment, including the impact of the COVID-19 pandemic, we are currently conducting the scientific activities described below with a view toward conserving financial resources.
ANA001, our lead drug candidate, is a proprietary oral niclosamide formulation and is being developed as a treatment for patients with moderate COVID-19. Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and well-understood safety in humans. Enrollment in the Phase 2 clinical trial of ANA001 for treatment of moderate COVID-19 in hospitalized patients was closed in July 2022 and the clinical trial moved to the data analysis phase. Our determination to close enrollment related in part to the challenges and delays caused by a decreased number of eligible subjects and a changing COVID-19 environment, which was due to a number of factors including, the high prevalence of COVID-19 immunity (through vaccination or previous infection), availability of alternate treatments, and decreased COVID-19 hospitalizations which in turn greatly limits the number of eligible subjects needed for the clinical trial. At the time of closure 48 participants had been enrolled which is statistically sufficient for us to analyze the clinical trial data and achieve the objective of the study, which was determining the safety and tolerability of ANA001 for treatment of COVID-19. Following an analysis of the clinical trial data, which is expected in the fourth quarter of 2022, the Company will be able to begin discussions with the Food and Drug Administration regarding the next steps in the clinical development of ANA001 for treatment of COVID-19.
NB-01. We have determined to cease development of NB-01 on the prior regulatory pathway and not to advance to Phase 3 clinical trials.
The Company is currently evaluating various alternatives regarding the NB-01 asset. These alternatives include two potential development pathways.
- Orphan drug. Development of NB-01 as an orphan drug is among the alternatives the Company is considering.
- Nutraceutical. The Company has considered marketing NB-01 as a nutraceutical (non-pharmaceutical) product, and the Company may re-explore this pathway if the identified rare disease indication for NB-01 does not proceed.
NB-02. In order to preserve operating capital, we have postponed continued work on the Investigation New Drug application to the FDA for NB-02 and the first human clinical trials for NB-02 until global health and macroeconomic conditions improve. We are also considering engaging with a strategic partner with respect to further development of NB-02.
Gemcabene. We are currently exploring additional therapeutic indications for Gemcabene that may strengthen our pipeline of assets, this includes COVID-19 in combination with ANA001.
Going Concern
We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future product candidates. To date, we have not generated any revenue from product sales, collaborations with other companies, government grants or any other source, and do not expect to generate any revenue in the foreseeable future, and have been dependent on funding operations through the sale of equity securities.
As of June 30, 2022, we had an accumulated deficit of $88.0 million. Our net losses were $3.3 million and $3.9 million for the three months ended June 30, 2022 and 2021, respectively, and $6.2 million and $7.2 million for the six months ended June 30, 2022 and 2021, respectively. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:
- pursue clinical development for any of our current product candidates;
- initiate preclinical studies and clinical trials with respect to any additional indications for our current product candidates and any future product candidates that we may pursue;
- acquire or in-license other product candidates and/or technologies;
- develop, maintain, expand and protect our intellectual property portfolio;
- hire additional clinical, scientific and commercial personnel;
- establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval;
- seek regulatory approvals for any product candidates that successfully complete clinical trials;
- establish a sales, marketing and distribution infrastructure and/or enter into partnership arrangements to commercialize any products for which we may obtain regulatory approval; or
- add administrative, operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, and to support our being a public reporting company
As of June 30, 2022, we had cash of $8.8 million. Operating at such level of scientific activity, we expect that our cash will be adequate to fund operations into the first quarter of 2023. Although we are exploring financing opportunities and carefully monitoring the capital markets, we do not yet have any commitments for additional financing and may not be successful in our efforts to raise additional funds. Any amounts raised will be used for further development of our product candidates and for other working capital purposes.
The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate our continuation as a going concern. We have not established a source of revenues and, as such, have been dependent on funding operations through the sale of equity securities. Since inception, we have experienced significant losses and incurred negative cash flows from operations. We expect to incur further losses over the next several years as we develop our business. We have spent, and expect to continue to spend, a substantial amount of funds in connection with implementing our business strategy.
These factors individually and collectively raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments or classifications that may result from our possible inability to continue as a going concern.
Results of Operations
The following table summarizes our operating results for the periods indicated:
(in thousands)
| Operating expenses: | | For the Three Months Ended June 30, 2022 | | 2021 | | Change | | For the Six Months Ended June 30, 2022 | | 2021 | | Change | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | | $982 | | $2,012 | | $(1,030) | | $1,902 | | $3,155 | | $(1,253) | |
| General and administrative | | 2,237 | | 1,914 | | 323 | | 4,192 | | 4,101 | | 91 | |
| Total operating expenses | | 3,219 | | 3,926 | | (707) | | 6,094 | | 7,256 | | (1,162) | |
| Loss from operations | | (3,219) | | (3,926) | | 707 | | (6,094) | | (7,256) | | 1,162 | |
| Interest income | | — | | 5 | | (5) | | — | | 11 | | (11) | |
| Other expense, net | | (84) | | — | | (84) | | (84) | | — | | (84) | |
| Loss before income taxes | | (3,303) | | (3,921) | | 618 | | (6,178) | | (7,245) | | 1,067 | |
| Provision for income taxes | | — | | — | | — | | — | | — | | — | |
| Net loss | | $(3,303) | | $(3,921) | | $618 | | $(6,178) | | $(7,245) | | $1,067 | |
| | | | | | | | | | | | | | |
Comparison of Three Months Ended June 30, 2022 and 2021
Research and Development Expenses
Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs to operations as incurred.
Research and development expenses were approximately $1.0 million for the three months ended June 30, 2022 as compared to approximately $2.0 million for the three months ended June 30, 2021. The approximate $1.0 million decrease was primarily related to reduced clinical trial activity and drug manufacturing costs of approximately $0.8 million as enrollment in our ANA 001 clinical trial slowed, and reduced payroll and consulting costs of approximately $0.2 million.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting, and audit services.
General and administrative expenses were approximately $2.2 million for the three months ended June 30, 2022, compared to approximately $1.9 million for the three months ended June 30, 2021. The increase of approximately $0.3 million in the current period was primarily due an increase in legal and professional fees of approximately $0.5 million, partly related to exploration of business opportunities, offset by a decrease in insurance costs of approximately $0.1 million, and decreases in payroll, professional fee and overhead costs in the aggregate of approximately $0.1 million.
Interest Income
Interest income for the three months ended June 30, 2022 was nominal. Interest Income for the three months ended June 30, 2021 was approximately $5,000.
Other Expense
During the three months ended June 30, 2022, the Company recorded approximately $0.1 million of other expense primarily related to the loss on sale of fixed assets.
Comparison of Six Months Ended June 30, 2022 and 2021
Research and Development Expenses
Research and development expenses were approximately $1.9 million for the six months ended June 30, 2022 as compared to approximately $3.2 million for the six months ended June 30, 2021. The approximate $1.3 million decrease was primarily related to reduced clinical trial activity and drug manufacturing costs of approximately $0.8 as enrollment for our ANA 001 clinical trial slowed and reduced payroll and consulting costs of approximately $0.4 million.
General and Administrative Expenses
General and administrative expenses were approximately $4.2 million for the six months ended June 30, 2022, compared to approximately $4.1 million for the six months ended June 30, 2021. The increase of approximately $0.1 million in the current period was primarily due an increase in legal and professional fees of approximately $0.4 million, partly related to the exploration of business opportunities, offset by a decrease in insurance costs of approximately $0.2 million, and decreases in payroll, professional fees and overhead costs in the aggregate of approximately $0.1 million.
Interest Income
Interest income for the six months ended June 30, 2022 was nominal. Interest Income for the six months ended June 30, 2021 was approximately $11,000.
Other Expense
During the six months ended June 30, 2022, the Company recorded approximately $0.1 million of other expense primarily related to the loss on sale of fixed assets.
Liquidity and Capital Resources
Cash Flows
The following table summarizes our cash flows for the periods indicated:
(in thousands)
| | | For the Six Months Ended June 30, 2022 | | 2021 | |
|---|---|---|---|---|---|
| Net cash used in operating activities | | $(7,546) | | $(9,728) | |
| Net cash provided by (used in) investing activities | | 8 | | (3) | |
| Net cash provided by financing activities | | — | | 9,164 | |
| Net decrease in cash | | $(7,538) | | $(567) | |
Operating Activities
During the six months ended June 30, 2022, cash used from operating activities was approximately $7.5 million, consisting of our net loss of approximately $6.2 million, changes in working capital cash usage in the amount of approximately $1.9 million. offset by non-cash expenses related primarily to stock-based compensation of approximately $0.5 million. The change in working capital consisted primarily of increases in our prepaid expenses due to the annual renewal of our insurance policies in January 2022 as well as due to decreases in our accrued liabilities associated with fluctuations of our operating expenses under the normal course of business.
During the six months ended June 30, 2021, cash used in operating activities was approximately $9.7 million, which consisted of our net loss of approximately $7.2 million, changes in working capital and cash usage in the amount of approximately $2.9 million offset by non-cash expenses related primarily to stock-based compensation and depreciation in the aggregate of approximately $0.4 million.
Investing Activities
Cash provided by investing activities was approximately $8,000 during the six months ended June 30, 2022 related to the sale of equipment. Cash used in investing activities during the six months ended June 30, 2022 was approximately $3,000 related to the purchase of equipment.
Financing Activities
There was no cash provided by financing activities during the six months ended June 30, 2022. During the six months ended June 30, 2021, net cash provided by financing activities was approximately $9.2 million, consisting of net proceeds from a private placement financing of approximately $9.1 million, and approximately $72,000 in proceeds received from the exercise of stock options.
Critical Accounting Policies and Estimates
Our financial statements are prepared in accordance with GAAP. These accounting principles require us to make estimates and judgments that can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the periods presented. We believe that the estimates and judgments upon which we rely are reasonably based upon information available to us at the time that we make these estimates and judgments. To the extent that there are material differences between these estimates and actual results, our financial results will be affected. The accounting policies that reflect our more significant estimates and judgments and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, included in our 2021 Form 10-K filed on March 31, 2022.
During the three and six months ended June 30, 2022, there were no material changes to our critical accounting policies or estimates disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2021 Form 10-K filed on March 31, 2022.
Recent Accounting Pronouncements
Refer to Note 2— Summary of Significant Accounting Policies to our condensed consolidated financial statements included elsewhere in this report for a discussion of recently issued accounting pronouncements.
Controls and procedures
As filed, 4,843 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information we are required to disclose in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and financial officer, as appropriate, to allow timely decisions regarding required disclosure.
We designed and evaluate our disclosure controls and procedures recognizing that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance and not absolute assurance of achieving the desired control objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
Under the supervision of and with the participation of our management, including our principal executive and financial officer, we evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15(d)- 15(e) promulgated under the Exchange Act as of June 30, 2022. Based on this evaluation, our principal executive and financial officer concluded that our disclosure controls and procedures were not effective as of June 30, 2022 as a result of the material weaknesses described below and previously reported in our 2021 Form 10-K.
In connection with the preparation of the financial statements included in our 2021 Form 10-K, management identified material weaknesses resulting from a lack of segregation of duties over financial reporting, and logical access over computer applications. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Specifically, there was a lack of segregation of duties involved in the execution of wire transfers, preparing journal entries, and review over clinical trial accruals, and certain individuals in the accounting department have administrative access to the financial reporting systems. See “Remediation Efforts to Address the Material Weaknesses” below for steps we are taking to correct these material weaknesses.
Changes in Internal Control Over Financial Reporting
Except as provided below under “Remediation Efforts to Address Material Weaknesses,” there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Remediation Efforts to Address Material Weaknesses
We are in the process of remediating, but have not yet remediated, the material weaknesses described above. Under the oversight of the audit committee, management is developing a detailed plan and timetable for the implementation of appropriate remedial measures to address the material weaknesses. As of the date of this quarterly report, we have taken the following actions and are in the process of making the following changes in our internal control environment to help remediate the material weaknesses:
- we will enhance the controls over wire disbursements, separating the functions of initiating and wiring to two separate individuals;
- we have improved processes in the area of clinical site expense monitoring, including increasing communication between our accounting and clinical personnel, as well as with our clinical vendors;
- We will implement enhanced controls relative to the review and oversight of the accounting for clinical trial expenses and the review of journal entries.
- We will restrict administrator rights to only those individuals who require access.
Management may decide to take additional measures to remediate the material weaknesses as necessary.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$3.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$6.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-04-01 to 2022-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$3.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$6.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | −$0.12 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | −$0.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$0.12 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$0.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 26,661,771 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 26,661,771 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$7.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-06-30 | $8.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $10.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $10.1m | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $1.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $1.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-06-30 | $8.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-22-013500. Last ingested by Listed: Nov 14, 2026, 11:33 ET. Listed shows no prices and gives no investment advice.